Renal effects with Novartis's Reclast highlighted in FDA drug safety newsletter
This article was originally published in Scrip
Executive Summary
Novartis's injectable osteoporosis therapy Reclast (zoledronic acid) has been associated with 24 cases of renal impairment and acute renal failure since its 2007 approval, the US FDA said in the recent issue of its drug safety newsletter.